Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Life Sciences Xi L.P. Frazier purchased 588,235 shares of Attovia Therapeutics stock in a transaction dated Thursday, August 6th. The stock was bought at an average price of $17.00 per share, for a total transaction of $9,999,995.00. Following the completion of the purchase, the insider owned 6,154,213 shares in the company, valued at $104,621,621. This represents a 10.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Attovia Therapeutics Trading Down 1.0%
Shares of NASDAQ:ATTO opened at $20.17 on Friday. Attovia Therapeutics, Inc. has a one year low of $18.64 and a one year high of $22.79.
Hedge Funds Weigh In On Attovia Therapeutics
An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. grew its position in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.
About Attovia Therapeutics
Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.
Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.
Featured Stories
- Five stocks we like better than Attovia Therapeutics
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Receive News & Ratings for Attovia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Attovia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
